Astera Labs, Inc. $ALAB Shares Sold by StoneCrest Wealth Management Inc.

StoneCrest Wealth Management Inc. lowered its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 91.8% in the second quarter, HoldingsChannel reports. The firm owned 584 shares of the company’s stock after selling 6,569 shares during the period. StoneCrest Wealth Management Inc.’s holdings in Astera Labs were worth $282,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of ALAB. Royal Bank of Canada raised its position in shares of Astera Labs by 167.3% in the 1st quarter. Royal Bank of Canada now owns 152,453 shares of the company’s stock valued at $9,097,000 after purchasing an additional 95,409 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Astera Labs by 213.4% in the first quarter. AQR Capital Management LLC now owns 11,391 shares of the company’s stock worth $680,000 after buying an additional 7,756 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Astera Labs by 917.3% in the first quarter. Empowered Funds LLC now owns 4,639 shares of the company’s stock worth $277,000 after buying an additional 4,183 shares during the last quarter. First Trust Advisors LP raised its holdings in Astera Labs by 102.0% in the second quarter. First Trust Advisors LP now owns 112,766 shares of the company’s stock valued at $10,196,000 after acquiring an additional 56,952 shares in the last quarter. Finally, Brown Advisory Inc. raised its holdings in Astera Labs by 54.9% in the second quarter. Brown Advisory Inc. now owns 5,581 shares of the company’s stock valued at $505,000 after acquiring an additional 1,977 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Buying and Selling at Astera Labs

In other Astera Labs news, General Counsel Philip Mazzara sold 796 shares of Astera Labs stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $291.03, for a total value of $231,659.88. Following the completion of the transaction, the general counsel directly owned 103,343 shares in the company, valued at $30,075,913.29. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Manuel Alba sold 8,491 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $458.38, for a total value of $3,892,104.58. Following the transaction, the director directly owned 286,863 shares of the company’s stock, valued at $131,492,261.94. This trade represents a 2.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,244,395 shares of company stock worth $358,865,571. 10.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. UBS Group reissued a “neutral” rating and set a $425.00 price objective on shares of Astera Labs in a report on Wednesday. Roth Capital restated a “buy” rating and issued a $450.00 target price on shares of Astera Labs in a research note on Wednesday. Morgan Stanley increased their price target on shares of Astera Labs to $335.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Northland Securities downgraded Astera Labs from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Finally, Evercore reissued an “outperform” rating and issued a $297.00 price objective on shares of Astera Labs in a report on Tuesday, May 19th. Thirteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $325.25.

Astera Labs Price Performance

Astera Labs stock opened at $334.17 on Monday. Astera Labs, Inc. has a 12 month low of $97.89 and a 12 month high of $499.48. The company has a fifty day moving average price of $360.45 and a two-hundred day moving average price of $235.65. The company has a market cap of $57.98 billion, a PE ratio of 165.43 and a beta of 3.84.

Astera Labs (NASDAQ:ALAB) last issued its earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The company had revenue of $392.40 million for the quarter, compared to analysts’ expectations of $360.85 million. During the same period in the prior year, the company earned $0.44 earnings per share. The firm’s revenue was up 104.5% compared to the same quarter last year. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Equities research analysts anticipate that Astera Labs, Inc. will post 1.86 earnings per share for the current year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.